Versucht aus den Beispielen menschlicher Übersetzungen das Übersetzen zu lernen.
Von professionellen Übersetzern, Unternehmen, Websites und kostenlos verfügbaren Übersetzungsdatenbanken.
oclacitinib modulates the immune system and may increase susceptibility to infection and exacerbate neoplastic conditions.
oclacitinib jimmodula s-sistema immunitarja u jista’ jżid is-suxxettibbiltà għall-infezzjoni u jiggrava kundizzjonijiet neoplastiċi.
the observed neoplastic changes are well known hormonal and centrally mediated effects in the rat which are not relevant for humans.
il-bidliet neoplastiċi osservati huma effetti ormonali u medjati ċentralment magħrufa sew fil-far li mhumiex rilevanti għall- bnedmin.
capecitabine accord should only be prescribed by a qualified physician experienced in the utilisation of anti-neoplastic medicinal products.
capecitabine accord għandu jiġi preskritt biss minn tobba kkwalifikati b’esperjenza fl-użu ta’ prodotti mediċinali anti-neoplastiċi.
in a study to assess potential carcinogenicity in transgenic rash2 mice, no treatment related increases in the incidence of neoplastic lesions were observed.
fi studju biex jevalwa l-karċinoġeniċità potenzjali fi ġrieden transġeniċi rash2, ma kienu osservati l-ebda żiediet relatati mal-kura fl-inċidenza ta’ leżjonijiet neoplastiċi.
non-neoplastic lesions not identified in earlier preclinical studies were the cardiovascular system, pancreas, endocrine organs and teeth.
leżjonijiet mhux neoplastiċi li ma kienux identifikati fi studji ta’ qabel l-użu kliniku kienu s-sistema kardjovaskolari, il-pankreas, l-organi endokrini u s-snien.
anti-neoplastic, immunomodulatory or immunosuppressive therapies should not be co-administered due to the risk of additive immune system effects.
terapiji anti-neoplastiċi, immunomodulatorji jew immunosoppressivi m’għandhomx jingħataw flimkien minħabba r-riskju ta’ effetti addittivi fuq is-sistema immuni.
tecfidera has not been studied in combination with anti-neoplastic or immunosuppressive therapies and caution should, therefore, be used during concomitant administration.
tecfidera ma ġiex studjat flimkien ma’ terapiji antineoplastiċi jew immunosoppressivi u għalhekk għandha tintuża kawtela matul l-għoti fl-istess ħin.
the lenalidomide mechanism of action includes anti-neoplastic, anti-angiogenic, pro-erythropoietic, and immunomodulatory properties.
il-mekkaniżmu ta’ l-azzjoni ta’ lenalidomide jinkludi proprjetajiet anti-neoplastiċi, anti-anġjoġeniċi, pro-eritropojetiċi, u immunomodulatorji.
risk factors associated with interstitial lung disease include prior or concomitant therapy with other anti-neoplastic therapies known to be associated with it such as taxanes, gemcitabine, vinorelbine and radiation therapy.
fatturi ta’ riskju assoċjati ma’ mard tal-interstizu tal-pulmuni jinkludu terapija qabel jew fl-istess waqt b’terapiji anti-neoplastiċi oħra magħrufa li huma assoċjati ma dan bħal taxanes, gemcitabine, vinorelbine u terapija ta’ radjazzjoni.
culture-negative fever following treatment with cladribine occurs in 10-40% of patients with hairy cell leukaemia and is rarely observed in patients with other neoplastic disorders.
deni li huwa negattiv għall-koltura (‘culture-negative fever’) wara t-trattament bi cladribine iseħħ f’10-40% tal-pazjenti b’lewkimja taċ-ċelluli ċiljati u rarament kien osservat f’pazjenti b’mard neoplastiku ieħor.